Valitor has been awarded a Phase II SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will enable us to refine an IND-candidate for our lead compound, as well as to identify additional related applications for our multivalent protein conjugation technology.
Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised
Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi
Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the development of a long-acting anti-inflammat